TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

Phase 1/2 Completed 36 enrolled Centers for Disease Control and Prevention Columbia University · collab University of KwaZulu · collab Yale University · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluated the safety and tolerability of low-dose linezolid (600 mg once daily) administered for 16 weeks as part of an optimized background regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB).

Timeline

Start: 2009-04
Primary completion: 2010-09
Completion: 2010-09

Publications

Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Dec;16(12):1582-7. doi: 10.5588/ijtld.12.0315.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Linezolid	Other / unclassified	600 mg	Oral

TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

Summary

Timeline

Publications

Drugs

Indications